摘要
目的探讨重组人尿激酶原静脉溶栓治疗急性心肌梗死的效果及安全性。方法选取急性心肌梗死患者88例,并按照给药方案分为2组各26例。对照组采用尿激酶治疗,研究组应用重组人尿激酶原进行静脉溶栓治疗。比较2组患者血管再通率、出血率、血清肌酸激酶同工酶(CK-MB)峰值时间。结果研究组患者的血管再通率92. 31%,显著高于对照组69. 23%(P <0. 05)。研究组患者用药后出血率3. 85%,低于对照组15. 38%(P> 0. 05)。研究组患者的CK-MB峰值时间(11. 08±1. 89) h,显著短于对照组的(12. 75±2. 61) h (P <0. 05)。结论重组人尿激酶原静脉溶栓治疗急性心肌梗死的临床效果肯定。
Objective To explore the clinical efficacy and safety of intravenous thrombolysis of recombinant human prourokinase in treating patients with acute myocardial infarction.Methods A total of 88 patients with acute myocardial infarction were divided into two groups according to therapeutic regimen,with 26 cases in each group.The control group was treated with urokinase,while the study group was treated with recombinant human prourokinase for intravenous thrombolysis.The blood vessel recanalization rate,bleeding rate and peak time of serum creatine kinase isoenzyme(CK-MB)were compared between the two groups.Results The vascular recanalization rate of the study group was 92.31%,which was significantly higher than 69.23%of the control group(P<0.05).The bleeding rate of the study group was 3.85%,which was lower than 15.38%of the control group(P>0.05).The peak time of CK-MB in the study group was(11.08±1.89)h,which was significantly shorter than(12.75±2.61)h in the control group(P<0.05).Conclusion Intravenous thrombolysis of recombinant human prourokinase is effective and safe in treating patients with acute myocardial infarction.
作者
何霄
HE Xiao(Department of Cardiology,Longxian County People′s Hospital,Longxian,Shaanxi,721200)
出处
《实用临床医药杂志》
CAS
2019年第4期14-15,19,共3页
Journal of Clinical Medicine in Practice
关键词
重组人尿激酶原
尿激酶
静脉溶栓治疗
急性心肌梗死
不良反应
recombinant human prourokinase
urokinase
intravenous thrombolytic therapy
acute myocardial infarction
adverse reactions
